Mesoblast (MSB) Short Interest
Mesoblast (ASX:MSB) had 7.36% of shares reported as short positions as of 24 Aug 2026, representing 95,619,600 shares. Mesoblast operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Mesoblast
Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular medicines at scale.
Short position
Mesoblast (ASX:MSB) has 7.36% of its shares on issue reported as short positions as of 24 Aug 2026, or about 95,619,600 shares. Over the past 30 days that figure has fallen 0.19 percentage points, and over 90 days it has fallen 1.38 percentage points. Its highest recorded short interest was 10.28% in January 2021. MSB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4MSB intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Mesoblast
Latest MSB news
All news- Mesoblast (ASX:MSB): Business Update, FY26 Performance and Key Investor Watchpoints - Kalkine
googlenews
- Mesoblast (ASX:MSB) Shares Rally Meets Persistent Cash Burn - simplywall.st
googlenews
- Mesoblast earnings: Strong revenue growth and operational milestones in FY26
motleyfool
- MSB Annual Financial Results and Operational Update
asx
- Annual Financial Results Presentation
asx
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss MSB
Start a research thread or post the first pulse update